| Pay vs Performance Disclosure number in Millions | 12 Months Ended |
| Sep. 30, 2024 USD ($) | Sep. 30, 2023 USD ($) | Sep. 30, 2022 USD ($) | Sep. 30, 2021 USD ($) |
| Pay vs Performance Disclosure | | | | |
| Pay vs Performance Disclosure, Table | Value of Initial Fixed $100 Investment Based On: Year (1) (a) Summary Compensation Table Total for CEO Compensation Actually Paid to CEO (2) (c) Average Summary Compensation Table Total for Non-CEO NEOs Average Compensation Actually Paid to Non-CEO NEOs (3) (e) Total Shareholder Return Peer Group Total Shareholder Return (4) (g) Net Income Revenue (in millions) (5) (i) 2024 $ 7,620,611 $ 24,977,300 $ 2,683,449 $ 6,359,699 $ 59.47 $ 115.57 $ (280.7) $ 313.0 2023 $ 7,998,637 $ 3,219,824 $ 3,086,321 $ 1,648,641 $ 26.67 $ 95.05 $ (204.6) $ 245.1 2022 $ 5,917,663 $ (15,039,602) $ 2,484,123 $ (3,534,350) $ 46.39 $ 89.85 $ (217.9) $ 203.6 2021 $ 1,281,593 $ 18,054,219 $ 728,146 $ 6,408,876 $ 140.81 $ 120.21 $ (152.1) $ 132.3 __________________ | | | |
| Company Selected Measure Name | revenue | | | |
| Named Executive Officers, Footnote | The CEO and other NEOs for the indicated years were as follows: (i) for 2024, our CEO was Dr. Leproust and our other NEOs were Mr. Laponis, Dr. Finn, Ms. Green, Mr. Cho, Dr. Banyai, and Mr. Thorburn; (ii) for 2023, our CEO was Dr. Leproust and our other NEOs were Mr. Thorburn, Dr. Banyai, Dr. Finn, and Ms. Green; (iii) for 2022, our CEO was Dr. Leproust and our other NEOs were Mr. Thorburn, Dr. Banyai, Dr. Finn, Mr. Cho, and Mr. Weiss; and (iv) for 2021, our CEO was Dr. Leproust and our other NEOs were Mr. Thorburn, Dr. Banyai, Dr. Finn, and Mr. Weiss. | | | |
| Peer Group Issuers, Footnote | For each indicated covered year, represents the cumulative TSR of the Nasdaq Biotechnology Index. (5) | | | |
| PEO Total Compensation Amount | $ 7,620,611 | $ 7,998,637 | $ 5,917,663 | $ 1,281,593 |
| PEO Actually Paid Compensation Amount | $ 24,977,300 | 3,219,824 | (15,039,602) | 18,054,219 |
| Adjustment To PEO Compensation, Footnote | Amounts reported in this column are based on total compensation reported for our CEO in the Summary Compensation Table for the indicated fiscal years and adjusted as shown in the tables below. Fair value of equity awards was computed in accordance with the Company’s methodology used for financial reporting purposes. Fiscal Year Summary Compensation Table Total Adjustment to Summary Compensation Table Total (1) Compensation Actually Paid 2024 $ 7,620,611 $ 17,356,689 $ 24,977,300 2023 $ 7,998,637 $ (4,778,813) $ 3,219,824 2022 $ 5,917,663 $ (20,957,265) $ (15,039,602) 2021 $ 1,281,593 $ 16,772,626 $ 18,054,219 __________________ (1) See table below for calculation of Adjustment to Summary Compensation Table Total Fiscal Year Deduction of Grant Date Fair Value of Current year Equity Awards Addition of Fair Value of Current Year Equity Awards at Fiscal Year End Additions (Deductions) for Change in Value of Prior Years’ Awards Unvested at Fiscal Year End Additions (Deductions) for Awards that are Granted and Vest in the Same Covered Fiscal Year Additions (Deductions) for Change in Value of Prior Years’ that Vested in Fiscal Year Adjustment to Summary Compensation Table Total 2024 $ (5,849,949) $ 13,837,233 $ 7,705,047 $ 1,178,291 $ 486,067 $ 17,356,689 2023 $ (6,632,151) $ 4,259,928 $ (1,518,003) $ 208,413 $ (1,097,000) $ (4,778,813) 2022 $ (4,521,127) $ 2,416,154 $ (11,693,150) $ 138,996 $ (7,298,138) $ (20,957,265) 2021 $ — $ — $ 9,403,372 $ — $ 7,369,254 $ 16,772,626 | | | |
| Non-PEO NEO Average Total Compensation Amount | $ 2,683,449 | 3,086,321 | 2,484,123 | 728,146 |
| Non-PEO NEO Average Compensation Actually Paid Amount | $ 6,359,699 | 1,648,641 | (3,534,350) | 6,408,876 |
| Adjustment to Non-PEO NEO Compensation Footnote | Amounts reported in this column are based on the average of the total compensation reported for our other NEOs in the Summary Compensation Table for the indicated fiscal years and adjusted as shown in the tables below. Fair value of equity awards was computed in accordance with the Company’s methodology used for financial reporting purposes. Fiscal Year Average Summary Compensation Table Total Adjustment to Average Summary Compensation Table Total (1) Average Compensation Actually Paid 2024 $ 2,683,449 $ 3,676,250 $ 6,359,699 2023 $ 3,086,321 $ (1,437,680) $ 1,648,641 2022 $ 2,484,123 $ (6,018,473) $ (3,534,350) 2021 $ 728,146 $ 5,680,730 $ 6,408,876 __________________ (1) See table below for calculation of Adjustment to Average Summary Compensation Table Total Fiscal Year Deduction of Grant Date Fair Value of Current Year Addition of Fair Value of Current Year Equity Awards at Fiscal Year End Additions (Deductions) for Change in Value of Prior Years’ Awards Unvested at Fiscal Year End Additions (Deductions) for Awards that are Granted and Vest in the Same Covered Fiscal Year Additions (Deductions) for Change in Value of Prior Years’ that Vested in Fiscal Year Adjustment to Average Summary Compensation Table Total 2024 $ (1,855,631) $ 3,422,378 $ 1,713,610 $ 254,130 $ 141,763 $ 3,676,250 2023 $ (2,319,610) $ 1,220,625 $ (554,184) $ 97,636 $ 117,853 $ (1,437,680) 2022 $ (1,795,865) $ 975,053 $ (3,248,755) $ 49,024 $ (1,997,930) $ (6,018,473) 2021 $ — $ — $ 3,217,733 $ — $ 2,462,997 $ 5,680,730 | | | |
| Tabular List, Table | Revenue • Adjusted Gross Profit • | | | |
| Total Shareholder Return Amount | $ 59.47 | 26.67 | 46.39 | 140.81 |
| Peer Group Total Shareholder Return Amount | 115.57 | 95.05 | 89.85 | 120.21 |
| Net Income (Loss) | $ (280,700,000) | $ (204,600,000) | $ (217,900,000) | $ (152,100,000) |
| Company Selected Measure Amount | 313 | 245.1 | 203.6 | 132.3 |
| PEO Name | Dr. Leproust | | | |
| Additional 402(v) Disclosure | In accordance with SEC rules, the Company is required to include in the Pay versus Performance table the “most important” financial performance measure (as determined by the Company) used to link compensation actually paid to our NEOs to Company performance for the most recently completed fiscal year. The Company determined revenue, which is a metric included in our incentive program, meets this requirement and therefore, we have included this performance measure in the Pay versus Performance table. | | | |
| Measure:: 1 | | | | |
| Pay vs Performance Disclosure | | | | |
| Name | Revenue | | | |
| Measure:: 2 | | | | |
| Pay vs Performance Disclosure | | | | |
| Name | Adjusted Gross Profit | | | |
| Measure:: 3 | | | | |
| Pay vs Performance Disclosure | | | | |
| Name | Ending Cash Balance | | | |
| PEO | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | $ 17,356,689 | $ (4,778,813) | $ (20,957,265) | $ 16,772,626 |
| PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | 13,837,233 | 4,259,928 | 2,416,154 | 0 |
| PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | 7,705,047 | (1,518,003) | (11,693,150) | 9,403,372 |
| PEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | 1,178,291 | 208,413 | 138,996 | 0 |
| PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | 486,067 | (1,097,000) | (7,298,138) | 7,369,254 |
| PEO | Deduction of Grant Date Fair Value of Current Year [Member] | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | (5,849,949) | (6,632,151) | (4,521,127) | 0 |
| Non-PEO NEO | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | 3,676,250 | (1,437,680) | (6,018,473) | 5,680,730 |
| Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | 3,422,378 | 1,220,625 | 975,053 | 0 |
| Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | 1,713,610 | (554,184) | (3,248,755) | 3,217,733 |
| Non-PEO NEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | 254,130 | 97,636 | 49,024 | 0 |
| Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | 141,763 | 117,853 | (1,997,930) | 2,462,997 |
| Non-PEO NEO | Deduction of Grant Date Fair Value of Current Year [Member] | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | $ (1,855,631) | $ (2,319,610) | $ (1,795,865) | $ 0 |
